Why don’t more patients receive intravenous rt-PA for acute stroke?

References

• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7
   PubMed Web of Science ®Google Scholar
• Report of the Quality Standards Subcommittee of the American Academy of N. Thrombolytic therapy for acute ischemic stroke–Summary Statement. Neurology 1996;47:835
   PubMed Web of Science ®Google Scholar
• Adams HPJr, Brott TG, et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996;94:1167
   PubMed Web of Science ®Google Scholar
• Caplan L, Mohr JP, Kistler JP, Koroshetz W. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis–not a panacea for ischemic stroke. New Engl J Med 1997;337:1309
   PubMed Web of Science ®Google Scholar
• Hoffman JR. Thrombolytic therapy for acute ischemic stroke - Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative? Cjem 2001;3(3):183-5
   PubMedGoogle Scholar
• Hoffman JR. Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little. Med J Aust 2003;179(7):333-4
   PubMedGoogle Scholar
• Mann J. Truths about the NINDS study: setting the record straight. West J Med 2002;176(3):192-4
   PubMedGoogle Scholar
• Sinclair SE, Frighetto L, Loewen PS, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001;19(9):927
   PubMedGoogle Scholar
• Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883
   PubMed Web of Science ®Google Scholar
• Group ISTc. Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379(9834):2352-63
   PubMedGoogle Scholar
• Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781
   PubMed Web of Science ®Google Scholar
• Group Nr-PSS. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke 2000;31:2912
   PubMedGoogle Scholar
• Lyden P, Lu M, Kwiatkowski TG, et al. Thrombolysis in patients with transient neurologic deficits. Neurology 2001;57:2125
   PubMedGoogle Scholar
• Group Nr-PSS. Generalized Efficacy of t-PA for acute Stroke. Stroke 1997;28:2119
   PubMedGoogle Scholar
• Sandercock P, Lindley R, Wardlaw J, et al. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials 2011;12(1):252
   PubMedGoogle Scholar
• Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-29
   PubMed Web of Science ®Google Scholar
• Sandercock P, Lindley R, Wardlaw J, et al. Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials 2008;9:37
   PubMedGoogle Scholar
• Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384(9958):1929-35
   PubMed Web of Science ®Google Scholar
• Clinical Policy: Use of Intravenous tPA for the management of acute ischemic stroke in the emergency department. Ann Emerg Med 2013;61(2):225-43
   PubMedGoogle Scholar
• Lenzer J. Alteplase for stroke: money and optimistic claims buttress the “brain attack” campaign. BMJ 2002;324(7339):723-9
   PubMedGoogle Scholar
• Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics–2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2006;113(6):e85-151
   PubMed Web of Science ®Google Scholar
• Albright KC, Branas CC, Meyer BC, et al. ACCESS: acute cerebrovascular care in emergency stroke systems. Arch Neurol 2010;67(10):1210-18
   PubMed Web of Science ®Google Scholar
• Tveiten A, Mygland A, Ljostad U, Thomassen L. Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre. Emerg Med J 2009;26(5):324-6
   PubMedGoogle Scholar
• Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med 2010;5(7):406-9
   PubMed Web of Science ®Google Scholar
• Schwamm LH, Ali SF, Reeves MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes 2013;6(5):543-9
   PubMed Web of Science ®Google Scholar
• Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38(11):3055-62
   PubMedGoogle Scholar
• Davis PH, Torner JC, Holmes J, et al. Lifetime cost of stroke in the United States. Stroke 1996;27:1459
   PubMedGoogle Scholar